Bicara Therapeutics, Inc. (BCAX)
9.71
-0.05
(-0.51%)
USD |
NASDAQ |
Oct 29, 16:00
9.40
-0.31
(-3.19%)
After-Hours: 20:00
Bicara Therapeutics Enterprise Value : 147.39M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 147.39M |
| October 27, 2026 | 656.38M |
| October 26, 2026 | 617.48M |
| October 23, 2026 | 629.35M |
| October 22, 2026 | 664.95M |
| October 21, 2026 | 684.73M |
| October 20, 2026 | 713.74M |
| October 19, 2026 | 655.72M |
| October 16, 2026 | 610.23M |
| October 15, 2026 | 665.61M |
| October 14, 2026 | 647.15M |
| October 13, 2026 | 647.15M |
| October 12, 2026 | 646.49M |
| October 09, 2026 | 657.70M |
| October 08, 2026 | 641.87M |
| October 07, 2026 | 586.49M |
| October 06, 2026 | 595.72M |
| October 05, 2026 | 643.85M |
| October 02, 2026 | 666.27M |
| October 01, 2026 | 703.85M |
| September 30, 2026 | 730.88M |
| September 29, 2026 | 727.59M |
| September 28, 2026 | 743.41M |
| September 25, 2026 | 770.44M |
| September 24, 2026 | 808.02M |
| Date | Value |
|---|---|
| September 23, 2026 | 854.50M |
| September 22, 2026 | 1.006B |
| September 21, 2026 | 955.05M |
| September 18, 2026 | 996.58M |
| September 17, 2026 | 993.29M |
| September 16, 2026 | 954.39M |
| September 15, 2026 | 998.56M |
| September 14, 2026 | 1.034B |
| September 11, 2026 | 1.008B |
| September 10, 2026 | 1.027B |
| September 09, 2026 | 1.063B |
| September 08, 2026 | 1.067B |
| September 04, 2026 | 1.032B |
| September 03, 2026 | 1.043B |
| September 02, 2026 | 1.057B |
| September 01, 2026 | 1.048B |
| August 31, 2026 | 1.028B |
| August 28, 2026 | 1.049B |
| August 27, 2026 | 1.141B |
| August 26, 2026 | 1.134B |
| August 25, 2026 | 1.124B |
| August 24, 2026 | 1.059B |
| August 21, 2026 | 1.080B |
| August 20, 2026 | 1.112B |
| August 19, 2026 | 1.209B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.272B |
| Oncolytics Biotech, Inc. | 51.37M |
| Sangamo Therapeutics, Inc. | 40.63M |
| Sarepta Therapeutics, Inc. | 2.298B |
| Anixa Biosciences, Inc. | 101.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.44M |
| Total Expenses (Quarterly) | 55.44M |
| EPS Diluted (Quarterly) | -0.8161 |
| Earnings Yield | -31.78% |
| Normalized Earnings Yield | -31.78 |